Multiple Myeloma

Revimid Demonstrates Antitumor Activity In Phase I/II Clinical Trials

Published in Cancer Weekly, January 8th, 2002

Kenneth Anderson, MD, from the Dana-Farber Cancer Institute at Harvard University and Bart Barlogie, MD, PhD, from the Arkansas Cancer Research Center and their colleagues presented new clinical data at the 43rd annual meeting of the American Society of Hematology from two Phase I/II trials of Revimid in refractory and relapsed multiple myeloma.

The investigators reported that Revimid demonstrated significant antitumor activity and was generally well tolerated in patients.

"These encouraging results continue to validate our pipeline of IMiD compounds and based on these data we will substantially expand the clinical development of Revimid," said Sol...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry